As we approach another fall and winter, which is known to many as flu season, we must recognize that this is respiratory syncytial virus (RSV) season as well. We discuss the diagnosis and treatment of RSV and what you need to know about this highly contagious, yet often less discussed, seasonal respiratory virus (RSV). While RSV often presents with only mild symptoms, it is a leading cause of bronchitis and pneumonia. Older adults and adults with underlying health conditions, as well as young children, are most at risk of serious complications from this highly contagious virus.

There is likely an underestimation of RSV infections worldwide since many who are infected with RSV may not be diagnosed because its symptoms can be difficult to distinguish from the flu, COVID-19, or other respiratory infections. Helping patients, providers, and caregivers to recognize the risks and symptoms associated with RSV has the potential to significantly improve patient health outcomes.

In this episode, we welcome Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, at Janssen, and Patricia A. Stinchfield, R.N., M.S., CPNP, President-Elect of the National Foundation for Infectious Diseases (NFID), as they discuss the impact of the COVID-19 pandemic on the seasonality of RSV, the economic burden of the disease and more.

The IDViewpoints podcast was created by Janssen. Guests of IDViewpoints are not compensated in any way for participation in this podcast. All thoughts and opinions expressed on IDViewpoints are those of the guests and should not be considered medical advice. If you need medical advice or have questions about your treatment or condition, consult with your healthcare provider.